Holen Sie sich die Stockscreener-App
26.11
6.61%
1.62
Handel nachbörslich:
25.66
-0.45
-1.72%
Schlusskurs vom Vortag:
$24.49
Offen:
$24.38
24-Stunden-Volumen:
166.64K
Relative Volume:
8.44
Marktkapitalisierung:
$673.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+4.44%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$23.00
$26.52
1-Wochen-Bereich:
$21.24
$26.52
52-Wochen-Spanne:
$17.50
$28.98
Faeth Therapeutics Inc Stock (FTH) Company Profile
Firmenname
Faeth Therapeutics Inc
Sektor
Branche
Telefon
(240) 243-8000
Adresse
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare FTH vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FTH
Faeth Therapeutics Inc
|
26.11 | 631.32M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Faeth Therapeutics Inc Aktie (FTH) Neueste Nachrichten
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
BTIG Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Faeth Therapeutics CFO Stephenson buys $326,127 in FTH stock By Investing.com - Investing.com Australia
Faeth Therapeutics (FTH) CFO adds 13,634 shares via trust purchases - Stock Titan
Form 4 Faeth Therapeutics, Inc For: 1 July By Investing.com - Investing.com India
Faeth Therapeutics CFO Stephenson buys $326,127 in FTH stock - Investing.com
FTH SEC FilingsFaeth Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - Stocktwits
FTHFaeth Therapeutics Inc Latest SEC Filings - Finviz
Faeth Therapeutics, Inc.(NasdaqCM:FTH) added to Russell Microcap Value Benchmark Index - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM:FTH) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM: FTH) added to Russell 3000E Growth Benchmark - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM: FTH) added to Russell Microcap Index - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM: FTH) added to Russell 3000E Value Benchmark - marketscreener.com
Total current assets of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Faeth Therapeutics CFO Stephenson acquires $401,268 in stock By Investing.com - Investing.com Nigeria
Form 4 Faeth Therapeutics, Inc For: 26 June By Investing.com - Investing.com Australia
Faeth Therapeutics CFO Stephenson acquires $401,268 in stock - Investing.com
Faeth Therapeutics (FTH) CFO adds 15,641 shares via trust purchases - Stock Titan
FTH Initiates Coverage On Faeth Therapeutics -- Price Target Set at $57 - GuruFocus
This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Baird Initiates Faeth Therapeutics(FTH.US) With Buy Rating, Announces Target Price $57 - Moomoo
Baird Initiates Faeth Therapeutics at Outperform With $57 Price Target - marketscreener.com
Enterprise value to revenue forward of Faeth Therapeutics, Inc. – MUN:4070 - TradingView
Enterprise value to EBIT forward of Faeth Therapeutics, Inc. – MUN:4070 - TradingView
Baird initiates Faeth Therapeutics stock with outperform rating By Investing.com - Investing.com Nigeria
Price to sales forward of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Baird initiates Faeth Therapeutics stock with outperform rating - Investing.com
Enterprise value to EBITDA forward of Faeth Therapeutics, Inc. – MUN:4070 - TradingView
This Principal Financial Group Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday - Sahm
Price to earnings forward of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Faeth Therapeutics CEO Anand Parikh buys $55,446 in common stock By Investing.com - Investing.com India
FTH | Faeth Therapeutics, Inc. Common Institutional Ownership - Quiver Quantitative
Price to book forward of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
FTH Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Anand Parikh Increases Stake in Faeth Therapeutics Inc - GuruFocus
Faeth Therapeutics CEO Anand Parikh buys $55,446 in common stock - Investing.com UK
Faeth therapeutics CFO Brian C. Stephenson buys $405,920 in stock - Investing.com UK
Faeth therapeutics CFO Brian C. Stephenson buys $405,920 in stock By Investing.com - Investing.com Nigeria
FAETH THERAPEUTICS INC (FTH) Stock Chart - ChartMill
Form 4 Faeth Therapeutics, Inc For: 24 June By Investing.com - Investing.com Australia
FTH | Faeth Therapeutics, Inc. Common Stock Data, Price & News - Quiver Quantitative
Faeth Therapeutics (FTH) CFO adds 17,413 shares via revocable trust purchases - Stock Titan
Faeth Therapeutics CEO buys shares, exercises options | FTH Insider Trading - Stock Titan
Finanzdaten der Faeth Therapeutics Inc-Aktie (FTH)
Es liegen keine Finanzdaten für Faeth Therapeutics Inc (FTH) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Faeth Therapeutics Inc-Aktie (FTH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| STEPHENSON BRIAN C | Chief Financial Officer |
Jul 01 '26 |
Buy |
23.50 |
5,000 |
117,492 |
46,688 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 29 '26 |
Buy |
23.34 |
831 |
19,396 |
33,885 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 24 '26 |
Buy |
26.13 |
9,391 |
245,360 |
26,804 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 26 '26 |
Buy |
24.95 |
6,250 |
155,908 |
33,054 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 23 '26 |
Buy |
24.36 |
9,230 |
224,806 |
17,413 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 22 '26 |
Buy |
22.13 |
8,183 |
181,115 |
8,183 |
| Parikh Anand Kiran | President and CEO |
Jun 22 '26 |
Option Exercise |
1.16 |
53,465 |
62,019 |
817,699 |
| Parikh Anand Kiran | President and CEO |
Jun 22 '26 |
Buy |
19.76 |
2,806 |
55,447 |
764,234 |
| Cambrian BioPharma Inc | 10% Owner |
Jun 01 '26 |
Sale |
20.02 |
25,000 |
500,543 |
130,142 |
| Peyer James | 10% Owner |
Jun 01 '26 |
Sale |
20.02 |
25,000 |
500,543 |
130,142 |
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):